A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer

NCT01653574 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Famitinib Malate

Sponsor

Fudan University

Collaborators

[object Object]